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Objectives: To	 study	 the	 development	 of	 cognitive	 and	 emotional	 symptoms	 be‐
tween	3	and	12	months	after	a	minor	stroke.
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1  | INTRODUC TION
A	majority	of	ischemic	stroke	patients	have	mild	and	quickly	resolving,	




(TIA)	 can	 cause	persisting	disabling	 cognitive	 symptoms.2	A	 recent	
study	found	brain	atrophy	and	cognitive	decline	after	a	TIA	suggest‐
ing	 that	even	a	 transient	cerebrovascular	event	 leads	 to	secondary	
damage	in	the	brain3	independent	on	the	focal	ischemic	lesion.
Improvement	 of	 cognitive	 impairment	 occurs	 in	 a	 substantial	
amount	 of	 patients.	 One	 study	 found	 significant	 improvement	 of	
neuropsychological	test	results	from	baseline	to	6	and	12	months,	























where	 the	 vascular	 disease	 is	 the	 dominant	 pathology	 behind	 the	
cognitive	deficits.9













Emotional	 impairment	 is	 used	 to	 define	 anxiety	 and/or	
depression.
2.1 | Recruitment
Patients	were	 recruited	 consecutively	 from	 stroke	 units	 at	Molde	
Hospital,	 Haukeland	 University	 Hospital,	 and	 St	 Olav's	 Hospital.	
Patients	 from	 other	 participating	 stroke	 units	 in	 hospitals	 in	 the	
Central	 Norway	Health	 Authority	 (department	 of	 neurology	 at	 St	
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2.4 | Assessment of cognitive and 
emotional function
2.4.1 | Global and visuospatial cognitive function
Mini‐Mental	State	Examination12	and	clock	drawing	test13	were	used	












Informant	 questionnaire	 for	 cognitive	 decline	 in	 the	 elderly	





















In	 the	 linear	 regression	 analyses,	 change	 in	 results	 between	 3	













The	 mean	 age	 was	 58	 (SD	 10)	 years.	 Baseline	 mRS	 was	 0.3.	
Prevalent	risk	factors	were	hypertension	(54%),	BMI	>25	(58%),	hy‐
percholesterolemia	 (47%),	 and	 smoking	 (35%).	Assessment	of	 func‐
tion	status	by	mRS	score	prestroke	and	day	7/at	discharge	was	0.3	






Table	 2	 shows	 significantly	 lower	 prevalence	 of	 impairment	
in	 10‐Word	 test	 delayed	 recall,	 naming	 error	 test	 and	 impairment	


























































12 mo (%) Odds ratio P
Memory     
10‐word	learning	taska,b 7.7 6.0 2 .2
10‐word	learning	task,	
delayed recalla,b,c
14.0 7.8 2.9 .003
Executive	function     
Trail‐making	Aa 6.2 5.2 1.4 .6
Trail‐making	Ba 15.0 11.5 1.5 .3
Verbal	fluencya 14.2 11.2 1.8 .2
Color‐word	interference	
tests
    
Color‐word	naminga 25.2 20.1 2 .07
Color‐word	readinga 18.7 18.1 0.8 .6
Color‐word	inhibitiona 16.3 13.2 1.6 .2
Color‐word	inhibition/
switchinga
24.1 20.1 1.4 .2
Error	scores     
Naming	errorsd 7.8 5.2 1.4 .04
Reading	errorsd 13.0 10.0 1.7 .09
Inhibition	errorsa 12.9 5.9 1.3 .7
Inhibition/switching	
errorsa
6.9 8.7 0.6 .2
Impairment	≥2	cognitive	
tests
41.6 35.4 1.8 .03
Anxiety	and	depression     
HADSe 15 16 0.7 .3
HADS‐Af 20 18 1.3 .4
HADS‐Dg 9 12 0.4	(2.6) .04
Fatigue     

























TA B L E  3  Correlation	between	cognitive	function,	anxiety,	depression,	and	fatigue	at	12	mo	and	vascular	risk	factors	(Spearmans	test;	P)
 Hypertension Diabetes mellitus BMI >25 Atrial fibrillation Hyper cholesterolaemia Smoking
Global	cognitive	function	
and	visuospatial	test
      
MMSEa −0.1	(0.02) −0.08	(0.2) −0.07	(0.2) 0.02	(0.6) 0.04	(0.5) −0.1	(0.04)
Clock	drawing	test −0.01	(0.9) 0.07	(0.3) −0.06	(0.3) −0.04	(0.5) 0.05	(0.4) 0.02	(0.8)
Memory       
10‐word	learning	taskb −0.2	(0.003) −0.04	(0.5) −0.08	(0.2) −0.01	(0.8) −0.08	(0.2) −0.09	(0.1)
10‐word	learning	task	
delayed recallc
−0.1	(0.05) 0.02	(0.8) −0.1	(0.06) 0.05	(0.4) −0.05	(0.4) −0.1	(0.1)
Executive	function       
Trail‐making	A 0.1	(0.01) 0.06	(0.03) 0.09	(0.1) 0.05	(0.4) −0.07	(0.2) −2	(0.006)
Trail‐making	B 0.2	(0.002) −0.03	(0.6) 0.2	(0.004) 0.04	(0.5) −0.06	(0.3) 0.1	(0.03)
Verbal	fluency 0.02	(0.8) −0.05	(0.4) −0.01	(0.9) −0.05	(0.4) −0.01	(0.9) −0.1	(0.04)
Color‐word	interfer‐
ence	tests
      
Color‐word	namingd −0.01	(0.9) −0.07	(0.2) −0.05	(0.4) 0.05	(0.4) −0.02	(0.8) 0.1	(0.02)
Color‐word	readingd −0.05	(0.4) 0.01	(0.9) −0.04	(0.5) −0.01	(0.8) 0.05	(0.4) 0.2	(0.01)
Color‐word	
inhibitiond




−0.02	(0.7) −0.00	(1.0) −0.01	(0.9) 0.06	(0.3) 0.05	(0.4) 0.1	(0.04)
Naming	errorse 0.04	(0.5) 0.07	(0.2) 0.00	(0.9) −0.02	(0.8) −0.06	(0.3) −0.01	(	0.8)
Reading	errorse −0.03	(0.6) 0.03	(0.6) 0.03	(0.6) −0.02	(0.7) −0.05	(0.3) 0.05	(0.4)
Inhibition	errorsd 0.1	(0.04) −0.1	(0.8) 0.1	(0.01) −0.5	(0.3) 0.0	(0.7) 0.06	(0.3)
Inhibition/switching	
errorsd
−0.01	(0.8) −0.02	(0.6) 0.1	(0.04) −0.02	(0.7) 0.7	(0.3) 0.5	(0.3)
Anxiety	and	depression       
HADSf −0.08	(0.2) 0.05	(0.4) −0.01	(0.8) −0.02	(0.8) 0.01	(0.9) 0.00	(1.0)
HADS‐Ag −0.2	(0.01) 0.09	(0.1) −0.04	(0.4) −0.05	(0.4) −0.02	(0.8) −0.04	(0.5)
HADS‐Dh 0.01	(0.9) 0.2	(0.8) 0.01	(0.9) 0.02	(0.7) 0.03	(0.5) 0.05	(0.4)
Fatigue       
Fatigue	Severity	Scale	
(FSS)i
























We	 found	 no	 significant	 correlation	 between	 atrial	 fibrillation	
and	 cognitive	 impairment	 in	 contrast	 to	 another	 study.26	 The	 low	





    
MMSEa −0.11	(0.07) 0.08	(0.2) −0.07	(0.2) 0.04	(0.5)
Clock	drawing	test 0.08	(0.2) 0.04	(0.5) 0.07	(0.3) −0.08	(0.2)
Memory     
10‐word	learning	taskb −0.15	(0.02) −0.02	(0.7) −0.11	(0.07) −0.02	(0.7)
10‐word	learning	task	
delayed recallc
−0.08	(0.2) 0.08	(0.2) −0.08	(0.2) −0.2	(0.001)
Executive	function     
Trail‐making	A 0.003	(0.9) 0.06	(0.3) 0.08	(0.2) −0.2	(0.001)






    
Color‐word	namingd −0.08	(0.2) 0.04	(0.6) −0.16	
(0.008)
−0.03	(0.6)
Color‐word	readingd 0.08	(0.2) −0.06	(0.3) −0.10	(0.1) −0.04	(0.5)
Color‐word	
inhibitiond
−0.02	(0.8) 0.06	(0.3) −0.03	(0.6) −0.05	(0.4)
Color‐word	
inhibition/switchingd
0.02	(0.8) 0.04	(0.5) −0.08	(0.2) 0.07	(0.3)
Error	tests     
Naming	errore −0.03	(0.6) −0.05	(0.4) 0.04	(0.5) 0.01	(0.9)
Reading	errore −0.08	(0.2) 0.001	(0.9) −0.14	(0.03) 0.03	(0.7)
Inhibition	errord 0.06	(0.3) −0.03	(0.6) −0.04	(0.5) 0.16	(0.01)
Inhibition/switching	
errord
−0.02	(0.7) −0.07	(0.2) 0.06	(0.3) 0.13	(0.04)
Anxiety	and	depression     
HADSf 0.07	(0.2) 0.09	(0.2) −0.03	(0.6)  
HADS‐Ag 0.1	(0.1) 0.08	(0.2) 0.04	(0.5) 0.05	(0.4)
HADS‐Dh 0.02	(0.7) 0.08	(0.2) −0.1	(0.1)  
Fatigue     
Fatigue	Severity	Scale	
(FSS)










TA B L E  4  Regression	analyses	of	the	
difference	(raw	scores)	between	12	and	
3	mo,	beta	(P)

















High	prevalence	of	 overweight	may	 indicate	 that	 a	 consider‐












There	 was	 no	 significant	 difference	 in	 anxiety	 between	 3	 and	
12	months,	 but	 the	 prevalence	was	 relatively	 high	with	 20%	 and	
18%.	 A	 previous	 study	 using	 the	 same	 questionnaire	 (HADS)	 and	
same	cutoff	score	found	a	prevalence	of	anxiety	in	minor	stroke	pa‐
tients	of	25%	at	12	months.6
The	prevalence	of	 depression	was	 significant	 higher	with	12%	
at	12	months	 in	contrast	 to	9%	at	3	months.	This	 is	 in	contrast	 to	
another	 study	 which	 found	 a	 decrease	 over	 time	 from	 12.9%	 to	
8.1%	 between	 3	 and	 12	 months.32	 Patient	 characteristics	 in	 this	
study	were	quite	similar	except	higher	NIHSS	(2	vs	0.2).	One	study	



























One	 strength	of	 this	 study	 is	 the	 large	number	of	 patients.	 It	 is	 a	









elderly	was	 not	 registered	 at	 baseline.	A	 possibility	 of	 preexisting	
cognitive	 impairment,	 for	 example,	 early	 Alzheimer's	 disease	 may	
therefore	be	a	bias.
Prestroke	fatigue	and	obstructive	sleep	apnea	were	not	recorded.










The	prevalence	of	 depression	 increased	 from	3	 to	12	months.	
Early	detection	and	treatment	of	depression	is	important	to	contrib‐
ute	to	recovery	including	improvement	of	cognitive	symptoms.
Fatigue	 remains	 a	 persistent	 symptom	with	 a	 high	 prevalence	
1	year	after	a	minor	stroke.
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